The Moat Index
Compare moats, side by side.
Two to four companies, scored on the same five investor questions from their SEC filings — so the comparison is apples to apples. The method is fully public.
XBIO · Healthcare · Shallow moat
Doesn't clear the bar
The pricingPower component abstained: Not enough years of gross-margin data to score pricing power. The other four 20% weights were renormalized over the scored 80%.
| Measure | BLFS | XBIO | NUWE | PLUR |
|---|---|---|---|---|
| Moat Score (0–100) | 41 (highest) | 41 (highest) | 41 (highest) | 41 (highest) |
| Methodology version | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 | moat-index@3.0.0 |
| Business trend | 25 | 65 | 42 | 70 (highest) |
| Pricing power | 96 (highest) | — | 64 | 82 |
| Returns on capital | 4 (highest) | 0 | 0 | 0 |
| Balance-sheet safety | 55 (highest) | 55 (highest) | 55 (highest) | 28 |
| Capital allocation | 24 | 44 (highest) | 44 (highest) | 24 |
| No price data | No price data | No price data | No price data | |
| Market cap | $1.4B | $6M | $3.5M | $14.1M |
| Moat tier | Shallow moat | Shallow moat | Shallow moat | Shallow moat |
| Filing date | FY2025 | FY2025 | FY2025 | FY2025 |